We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+76.98%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.52B
AUM Growth
+$1.17B
Cap. Flow
+$333M
Cap. Flow %
9.47%
Top 10 Hldgs %
65.35%
Holding
41
New
13
Increased
13
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$95.9M
2
GMAB icon
Genmab
GMAB
+$93M
3
URGN icon
UroGen Pharma
URGN
+$75.7M
4
CDTX
Cidara Therapeutics
CDTX
+$61.3M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$57.6M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$85.3M
2
ONC
BeOne Medicines Ltd
ONC
+$84.2M
3
IRON icon
Disc Medicine
IRON
+$57.3M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$41.5M
5
LENZ
LENZ Therapeutics
LENZ
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$456M 12.96%
5,269,433
– –
MRUS
2
DELISTED
Merus
MRUS
$412M 11.71%
4,373,770
+91,816
+2% +$5.98M
ACLX
3
DELISTED
Arcellx
ACLX
$382M 10.86%
4,649,016
– –
RVMD icon
4
Revolution Medicines
RVMD
$40.2B
$291M 8.27%
6,223,291
+130,000
+2% +$5.09M
TARS icon
5
Tarsus Pharmaceuticals
TARS
$2.56B
$158M 4.51%
2,665,698
-310,401
-10% -$15.3M
PCVX icon
6
Vaxcyte
PCVX
$7.89B
$136M 3.88%
3,784,755
+411,918
+12% +$13.6M
ABVX
7
Abivax
ABVX
$11B
$133M 3.78%
+1,564,196
New +$95.9M
GMAB icon
8
Genmab
GMAB
$17.7B
$117M 3.33%
+3,816,851
New +$93M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.16B
$107M 3.05%
2,673,555
+1,531,044
+134% +$57.6M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.86B
$106M 3.02%
2,550,774
+207,221
+9% +$6.63M
XBI icon
11
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$100M 2.85%
+1,000,000
New +$90.1M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.39B
$100M 2.85%
6,170,131
+27,787
+0.5% +$394K
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$92M 2.62%
+961,164
New +$61.3M
URGN icon
14
UroGen Pharma
URGN
$2B
$84.1M 2.39%
+4,216,084
New +$75.7M
SRRK icon
15
Scholar Rock
SRRK
$5.71B
$74.8M 2.13%
2,009,745
+409,191
+26% +$14.3M
JANX icon
16
Janux Therapeutics
JANX
$935M
$71.4M 2.03%
2,920,258
– –
OLMA icon
17
Olema Pharmaceuticals
OLMA
$1.02B
$66.5M 1.89%
6,794,172
+30,000
+0.4% +$180K
APGE icon
18
Apogee Therapeutics
APGE
$10.2B
$60.5M 1.72%
1,521,757
+563,127
+59% +$21.5M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.13B
$56.3M 1.6%
2,609,353
-132,223
-5% -$2.38M
ALKS icon
20
Alkermes
ALKS
$8.82B
$51.6M 1.47%
1,719,334
+343,765
+25% +$9.69M
LENZ
21
LENZ Therapeutics
LENZ
$172M
$50M 1.42%
1,073,461
-643,605
-37% -$23.7M
PHVS icon
22
Pharvaris
PHVS
$2.39B
$45.8M 1.3%
1,835,494
+772,583
+73% +$17.1M
COGT icon
23
Cogent Biosciences
COGT
$6.79B
$45.3M 1.29%
3,156,398
-7,196,051
-70% -$85.3M
OCUL icon
24
Ocular Therapeutix
OCUL
$1.86B
$40.9M 1.16%
3,497,307
+76,967
+2% +$920K
BBIO icon
25
BridgeBio Pharma
BBIO
$16.5B
$35.5M 1.01%
684,277
-281,487
-29% -$13.7M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Paradigm Biocapital Advisors held 41 positions worth $3.52B, up 50% from $2.34B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Paradigm Biocapital Advisors deployed $333M of net new capital in Q3 2025, opening 13 new positions and adding to 13 existing holdings. Its largest new stake was Abivax: 1,564,196 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $85.3M trimmed.

  • Paradigm Biocapital Advisors's largest Q3 2025 buy was Abivax: 1,564,196 shares worth $133M.
  • Paradigm Biocapital Advisors added most to Agios Pharmaceuticals in Q3 2025, an estimated $57.6M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $85.3M.
  • Paradigm Biocapital Advisors fully exited BeOne Medicines Ltd in Q3 2025, selling an estimated $84.2M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $3.52B portfolio in Q3 2025.
  • Paradigm Biocapital Advisors opened 13 new positions and closed 5 in Q3 2025.
  • Paradigm Biocapital Advisors's portfolio value rose 50% quarter-over-quarter to $3.52B.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.